171 related articles for article (PubMed ID: 37653031)
1. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
Exp Mol Med; 2023 Oct; 55(10):2162-2176. PubMed ID: 37653031
[TBL] [Abstract][Full Text] [Related]
2. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the molecular interplay and tumorigenesis in hepatocellular carcinoma through insights into FBXL6 and KRAS
Cai Q; Shubhra QTH
Mil Med Res; 2024 Feb; 11(1):9. PubMed ID: 38326872
[No Abstract] [Full Text] [Related]
4. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
5. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice.
Lin XT; Zhang J; Liu ZY; Wu D; Fang L; Li CM; Yu HQ; Xie CM
Cell Rep; 2023 Jul; 42(7):112812. PubMed ID: 37450367
[TBL] [Abstract][Full Text] [Related]
6. Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner.
Qin Z; Xiang C; Zhong F; Liu Y; Dong Q; Li K; Shi W; Ding C; Qin L; He F
J Exp Clin Cancer Res; 2019 Apr; 38(1):154. PubMed ID: 30971297
[TBL] [Abstract][Full Text] [Related]
7. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
8. Author Correction: Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
Exp Mol Med; 2023 Oct; 55(10):2281-2286. PubMed ID: 37783772
[No Abstract] [Full Text] [Related]
9. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma.
Li X; Zhang CC; Lin XT; Zhang J; Zhang YJ; Yu HQ; Liu ZY; Gong Y; Zhang LD; Xie CM
Exp Mol Med; 2024 Feb; 56(1):177-191. PubMed ID: 38177295
[TBL] [Abstract][Full Text] [Related]
11. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
[TBL] [Abstract][Full Text] [Related]
12. Novel transketolase inhibitor oroxylin A suppresses the non-oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient-derived organoids.
Jia D; Liu C; Zhu Z; Cao Y; Wen W; Hong Z; Liu Y; Liu E; Chen L; Chen C; Gu Y; Jiao B; Chai Y; Wang HY; Fu J; Chen X
Clin Transl Med; 2022 Nov; 12(11):e1095. PubMed ID: 36314067
[TBL] [Abstract][Full Text] [Related]
13. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
Luo YD; Liu XY; Fang L; Yu HQ; Zhang YJ; Chen M; Zhang LD; Xie CM
Theranostics; 2022; 12(18):7903-7919. PubMed ID: 36451866
[No Abstract] [Full Text] [Related]
14. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
15. FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
Liu ZY; Lin XT; Zhang YJ; Gu YP; Yu HQ; Fang L; Li CM; Wu D; Zhang LD; Xie CM
Cancer Lett; 2023 Jul; 566():216257. PubMed ID: 37277019
[TBL] [Abstract][Full Text] [Related]
16. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
17. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
18. TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
Geng L; Zhu M; Luo D; Chen H; Li B; Lao Y; An H; Wu Y; Li Y; Xia A; Shi Y; Tong Z; Lu S; Xu D; Wang X; Zhang W; Sun B; Xu Z
Oncogene; 2024 Feb; 43(9):682-692. PubMed ID: 38216672
[TBL] [Abstract][Full Text] [Related]
19. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
[TBL] [Abstract][Full Text] [Related]
20. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
